New Oral Anticoagulant Drugs
dc.contributor.advisor | Pórszász, Róbert | |
dc.contributor.advisordept | Department of Pharmacology | hu_HU |
dc.contributor.author | Arraf, Nada | |
dc.contributor.department | DE--Általános Orvostudományi Kar | hu_HU |
dc.contributor.opponent | Drimba, László | |
dc.contributor.opponent | Szentmiklósi, József András | |
dc.contributor.opponentdept | Kenézy Kórház Központi Aneszteziológiai és Intezív Terápiás Osztály | hu_HU |
dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
dc.date.accessioned | 2019-09-24T11:40:03Z | |
dc.date.available | 2019-09-24T11:40:03Z | |
dc.date.created | 2019-04-12 | |
dc.description.abstract | Thrombosis and thromboembolic events are the major cause of mortality and morbidity nowadays.The traditional anticoagulant therapy includes vitamin K antagonists and heparin. However, warfarin's significant disadvantages including the variability in dose-response, the narrow therapeutic index, and the numerous drug and dietary interactions associated with this agent have led to the introduction of the new oral anticoagulants (NOACs).New oral anticoagulants (NOAC) are a group of drugs comprising of direct thrombin inhibitor (dabigatran) and direct factor Xa inhibitors (rivaroxaban and others). NOACs have major pharmacological benefits over warfarin including, much fewer food and drug interactions, having a fixed dose and not requiring frequent monitoring. | hu_HU |
dc.description.corrector | LB | |
dc.description.course | általános orvos | hu_HU |
dc.description.courselang | angol | hu_HU |
dc.description.degree | egységes, osztatlan | hu_HU |
dc.format.extent | 44 | hu_HU |
dc.identifier.uri | http://hdl.handle.net/2437/273693 | |
dc.language.iso | en | hu_HU |
dc.subject | Thrombosis | hu_HU |
dc.subject | Rivaroxaban (Xarelto) | hu_HU |
dc.subject | Apixaban(Eliquis) | hu_HU |
dc.subject | edoxaban (Savaysa®) | hu_HU |
dc.subject | NOACs | hu_HU |
dc.subject | Acute Coronary syndrome | hu_HU |
dc.subject | Idarucizumab | hu_HU |
dc.subject | andexanet alfa (Andexxa) | hu_HU |
dc.subject.dspace | DEENK Témalista::Orvostudomány | hu_HU |
dc.title | New Oral Anticoagulant Drugs | hu_HU |